title: Effects of anthopleurin-Q on myocardial hypertrophy in rats and physiologic properties of isolated atria in guinea pigs.
abstract: OBJECTIVE
  To study effects of anthopleurin-Q (AP-Q) on myocardial hypertrophy in rats and isolated atria in guinea pigs.
  
  
  METHODS
  Two myocardial hypertrophy models in rats were established, one introduced by levothyroxine, the other by stenosis of abdominal aorta. Cardiac myocytes morphometry and functional experiments were employed to investigate effects of AP-Q.
  
  
  RESULTS
  Low dose of AP-Q (1 microg/kg/d, ip) reduced morphologic changes of myocardial hypertrophy in both rat models. While high dose of AP-Q (10 microg/kg/d, ip) did not, and caused mild hydropic degeneration in cardiomyocytes. High concentration of AP-Q (30 nmol/L) enhanced the contractility, raised automaticity, and prolonged the functional refractory period (FRP) in isolated left atria of guinea pigs; higher concentration (100 nmol/L) triggered arrhythmia in right atria; low concentration of AP-Q (1 nmol/L)did not affect any myocardial properties above.
  
  
  CONCLUSIONS
  Low dose of AP-Q without inotropic effect can hinder the experimental myocardial hypertrophy in rats; high dose with positive inotropic effect may be responsible for its toxic reaction.
authors.affiliation: Department of Pharmacology, Tongji Medical College, Huazhong University of Science Technology, Wuhan 430030, China. zhouji88@hotmail.com
authors.forename: Ji
authors.initials: J
authors.lastname: Zhou
authors.forename: Li-Ying
authors.initials: LY
authors.lastname: Fu
authors.forename: Wei-Xing
authors.initials: WX
authors.lastname: Yao
authors.forename: Guo-Jin
authors.initials: GJ
authors.lastname: Xia
authors.forename: Ming-Xing
authors.initials: MX
authors.lastname: Jiang
authors.forename: Jing-Rui
authors.initials: JR
authors.lastname: Wang
authors.forename: Zhong-Gao
authors.initials: ZG
authors.lastname: Wu
authors.forename: Lin-Lin
authors.initials: LL
authors.lastname: Qian
mesh_terms: D000818:Animals; D001024:Aortic Valve Stenosis / Q000150:complications; D006332:Cardiomegaly / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D002316:Cardiotonic Agents / Q000494:pharmacology*; D006168:Guinea Pigs; D006325:Heart Atria / Q000187:drug effects / Q000503:physiopathology; D066298:In Vitro Techniques; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013974:Thyroxine
chemical_list: D002316:Cardiotonic Agents; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; C477842:anthopleurin-Q; D013974:Thyroxine